CIK 0001501697
- Non-accelerated filer
- Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273181608
- Phone
- +1 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series A-2 Convertible Preferred Stock | −13,256 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series A-2 Convertible Preferred Stock | −4,659 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series A-2 Convertible Preferred Stock | −6,801 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series B Convertible Preferred Stock | −710,817 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series B Convertible Preferred Stock | −13,854 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series B Convertible Preferred Stock | −4,869 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series B Convertible Preferred Stock | −7,108 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series C Convertible Preferred Stock | −221,638 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series C Convertible Preferred Stock | −4,315 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series C Convertible Preferred Stock | −1,516 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series C Convertible Preferred Stock | −2,213 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series D Convertible Preferred Stock | −2,153,746 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series D Convertible Preferred Stock | −41,976 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series D Convertible Preferred Stock | −14,752 | 0 | ||
| 2017-11-20 | MCGUIRE TERRANCE Director | Conversion · Series D Convertible Preferred Stock | −21,537 | 0 | ||
| 2017-11-20 | Gerngross Tillman U. Director | Conversion | +90,272 | 192,821 | ||
| 2017-11-20 | Gerngross Tillman U. Director | Purchase | +200,000 | $10.00 | $2.0M | 392,821 |
| 2017-11-20 | Gerngross Tillman U. Director | Conversion · Series D Convertible Preferred Stock | −308,099 | 0 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion | +19,533 | 19,533 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion | +252,230 | 271,763 |
Page 19 of 25 · 490 trades